Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cinrebafusp alfa - Pieris Pharmaceuticals/Servier

Drug Profile

Cinrebafusp alfa - Pieris Pharmaceuticals/Servier

Alternative Names: HER2/41BB bispecific; PRS-343

Latest Information Update: 23 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pieris Pharmaceuticals
  • Developer Eli Lilly and Company; Pieris Pharmaceuticals; Seagen
  • Class Antineoplastics; Immunotherapies; Lipocalins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastric cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gastric cancer
  • Phase I Solid tumours

Most Recent Events

  • 07 Sep 2022 Pieris Pharmaceuticals completes enrolment of patients in phase-II trial in Gastric cancer (Combination therapy, Second-line therapy or greater) in South Korea and USA(Parenteral) (NCT05190445) (Pieris Pharmaceuticals pipeline, November 2022)
  • 18 Jan 2022 Phase I trial is still ongoing in Solid tumours (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) and Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (IV) (NCT03650348) (NCT03330561)
  • 01 Nov 2021 Phase-II clinical trials in Gastric cancer (Combination therapy, Second-line therapy or greater) in South Korea (Parenteral) (NCT05190445)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top